EnVivo is developing a robust program of selective, orally active alpha 7 agonists for treatment of the cognitive decline in Alzheimer’s disease and Schizophrenia.
The program has successfully completed clinical Phase Ia testing (SAD & MAD) and has entered Phase Ib trials in Schizophrenia patients in April 2008 and is scheduled to enter Phase Ib in Alzheimer’s patients in September 2008.
The program was in-licensed from Bayer Healthcare and included an extensive and exclusive patent estate surrounding the compounds’ composition-of-matter.
EnVivo is developing a CNS-penetrant, orally bioavailable histone deactylase inhibitor (HDACi) that is being pursued for use as a cognition enhancing agent in neurodegenerative diseases with a potential for disease modification.
The program is currently in late stage pre-clinical development and is expected to enter clinical Phase I testing in Q4 2008.
EnVivo has an exclusive worldwide license from MethylGene, Inc.(Montreal, Québec; TSX:MYG, www.methylgene.com), to operate in the field of HDAC inhibitors for neurodegenerative diseases.
